Greater Glasgow and Clyde Medicines

Ronapreve® is now indicated in two distinct patient populations:

Group 1: Patients admitted unwell with COVID-19 who are negative for baseline serum anti-spike (anti-S) antibodies against SARS-CoV-2.

Group 2: Patients with early hospital onset COVID-19 who are at high risk of progression to severe COVID-19 or in whom COVID-19 infection presents a material risk of destabilising a pre-existing condition or illness or compromising recovery from surgery or other hospital procedure.

Guideline News for November 2021

Antiretrovirals for the treatment of HIV in Acute. 

Key Medicine Shortages for November 2021

Many liquid medicines have multiple concentrations; this applies to licensed and unlicensed preparations. Switching between concentrations is a known cause of dosing error.

New clinical guideline - Proton Pump Inhibitor Guideline for Neonates and Paediatrics. The guideline contains information on preferred choice of PPI, as well as dosage and administration advice.

The carbon footprint of inhalers was considered during the recent review of the NHSGGC COPD and adult asthma inhaler device guides (IDGs) (available on StaffNet). The IDGs now have a traffic light key which highlights if the inhaler has a very high, high or low carbon footprint.

Guideline News for October 2021

MHRA Drug Safety Update for October 2021